October 31, 2025

Single-Injection Omvoh Option Simplifies Ulcerative Colitis Care

The FDA approved Eli Lilly’s interleukin-23p19 antagonist Omvoh (mirikizumab-mrkz) as a once-monthly single-injection maintenance option for adults with moderately to severely active ulcerative colitis.

Conexiant

October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 29, 2025

Can SGLT-2 Inhibitors Shield Against Autoimmune Disease?

Researchers found sodium-glucose cotransporter-2 inhibitors lowered autoimmune rheumatic disease risk by 11% in adults with type 2 diabetes.

Conexiant

October 29, 2025

ACP Reaffirms Physicians’ Duty to Donor-Patients

ACP defines updated ethical rules ensuring fairness and trust in organ donation practices.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 22, 2025

Fall Vaccines: What’s New, What’s Not

Updated CDC fall vaccine guidance simplifies covid, flu, and RSV shots with broad access and minimal changes from last year.

KFF Health News

October 20, 2025

Obinutuzumab Wins FDA Nod for Lupus Nephritis

Roche's anti-CD20 antibody improved renal response and allowed for lower corticosteroid use in the phase III REGENCY trial, offering a twice-yearly maintenance option after initial dosing.

Conexiant

October 20, 2025

Tezepelumab FDA Approval Expands Use to Nasal Polyps

AstraZeneca and Amgen’s anti-thymic stromal lymphopoietin biologic reduces nasal polyp burden and corticosteroid use in the phase 3 WAYPOINT trial.

Conexiant

October 16, 2025

Hidden Disparities in Med Schools Uncovered

Researchers found that US medical students with disabilities—especially women of color—face higher rates of discrimination.

Conexiant